Journal
CANCERS
Volume 12, Issue 8, Pages -Publisher
MDPI
DOI: 10.3390/cancers12082191
Keywords
positron emission tomography; apoptosis; caspase-3; [F-18]ICMT-11; pyrimidoindolone; Michael acceptor
Categories
Ask authors/readers for more resources
Insufficient apoptosis is a recognised hallmark of cancer. A strategy to quantitatively measure apoptosis in vivo would be of immense value in both drug discovery and routine patient management. The first irreversible step in the apoptosis cascade is activation of the executioner caspase-3 enzyme to commence cleavage of key structural proteins. One strategy to measure caspase-3 activity is Positron Emission Tomography using isatin-5-sulfonamide radiotracers. One such radiotracer is [F-18]ICMT-11, which has progressed to clinical application. This review summarises the design and development process for [F-18]ICMT-11, suggesting potential avenues for further innovation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available